Akari Therapeutics PLC (AKTX)

[mick]

$AKTX NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE)
-- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter ended March 31, 2020,
as well as recent clinical progress.

“We remain focused on our mission of addressing severe inflammatory diseases with significant unmet medical need.

We are pleased that our company is now in the process of planning or undertaking pivotal trials in both BP and HSCT-TMA as well as progressing next clinical steps for studies in atopic keratoconjunctivitis (AKC) and COVID-19 pneumonia,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics.

Severe inflammatory diseases remain an area of high unmet need.
Akari continues to make progress driving its anti-inflammatory programs forward, including the recent announcement of positive topline results from our Phase II BP study in May.